Current treatment practices for anemia in patients with chronic kidney disease and future opportunities with hypoxia-inducible factor prolyl hydroxylase inhibitors: a narrative review.

Mercedes Kile, Patcharaporn Sudchada

Journal: International urology and nephrology 2021;53(2):283-290

PMID: 32770437

Abstract

To investigate current treatment practices for anemia in patients with chronic kidney disease (CKD), issues surrounding current treatment practices, and the hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) that are currently in clinical trials. Treatment of anemia in patients with CKD has traditionally included iron supplementation and erythropoiesis-stimulating agents (ESAs). However, due to adverse cardiovascular (CV) events and hypo-responsiveness to ESA therapy, new agents are currently in clinical trials to treat anemia in patients with CKD. The HIF-PHIs stimulate erythropoiesis and regulate iron metabolism and are attractive alternatives to iron supplementation and ESAs.

Address: School of Pharmacy, University of Wisconsin-Madison, Madison, WI, USA.; Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand. [email protected].

DOI: 10.1007/s11255-020-02584-x

Link outs

Free resources

Medical:

https://medlineplus.gov/anemia.html

Subscription / membership required

Full Text Sources:

https://doi.org/10.1007/s11255-020-02584-x

MeSH Terms: Anemia, Barbiturates, Forecasting, Glycine, Humans, Hypoxia-Inducible Factor-Proline Dioxygenases, Isoquinolines, Practice Patterns, Physicians', Renal Insufficiency, Chronic